CasL/HEF1 belongs to the p130Cas family. It is tyrosine-phosphorylated following β1 integrin and/or T cell receptor stimulation, and is thus considered to be important for immunological reactions. CasL has several structural motifs such as an SH3 domain and a substrate domain, and interacts with many molecules through these motifs. To obtain more insights on the CasL-mediated signal transduction, we sought for proteins that interact with the CasL SH3 domain by Far-Western screening, and identified a novel human molecule, MICAL (a Molecule Interacting with CasL).
INTRODUCTION
CasL (also known as HEF1) was originally identified as a highly phosphorylated protein of 105-kDa in human lymphocytes after β1 integrin stimulation (1) (2) (3) . CasL is expressed preferentially in lymphocytes and several epithelial cells. It belongs to the p130Cas (Cas) family that includes Cas, CasL/HEF1, and Efs/Sin (4-6). They contain an SH3 domain at the NH2-terminus, followed by a substrate domain composed of a cluster of potential SH2-binding sites, and a COOH-terminal domain which contains consensus binding motifs for the SH3 and SH2 domains of c-Src (CasL does not have binding motifs for c-Src SH3 domain). This structural profile indicates that the Cas family proteins serve as docking molecules that assemble and transduce intracellular signals.
Since Cas was the first characterized member of the Cas family proteins, the study of Cas is most advanced and it has established a framework for the studies of the other family members. In fibroblasts, Cas has been shown to reside primarily at focal adhesions and along adhesion-proximal regions of stress fibers (7, 8) , where Cas associates with focal adhesion kinase (FAK) (9) . When cells attach to extracellular matrix proteins such as fibronectin, laminin, or vitronectin through integrin molecules, they form focal adhesion structures (also simply called "focal adhesions") at the adhesion sites. At focal adhesions, stress fibers are tethered, and a variety of molecules that mediate many cellular functions such as proliferation and migration Rabbit antisera against MICAL C1 and C2 were obtained as described below.
Polyclonal antibodies were purified from these antisera by affinity chromatography (HiTrap NHS-activated: Pharmacia, described below). Mouse monoclonal antibody (mAb) V9 against vimentin and mAb M2 against the FLAG epitope were purchased from SIGMA. Rabbit polyclonal antibody HA.11 against the hemagglutinin (HA) epitope was obtained from BAbCO. Goat polyclonal antibodies C-20 against vimentin and N-17 against CasL/HEF1 were purchased from Santa Cruz. The mAb 9E10 against the Myc epitope was obtained by culturing 9E10 hybridomas in the non-serum culture system. Fluorescein (FITC)-conjugated anti-rabbit donkey antibody and Texas red-conjugated anti-goat donkey antibody were purchased from Jackson Laboratories Inc. The human thymus 5'-STRETCH PLUS cDNA library (HL5010b) was purchased from CLONETECH, and was used in the Far-Western screening.
Far-Western Screening.
The cDNA fragment encoding the human CasL SH3 domain (amino acid residues 2-66) was generated by PCR reaction using customized primers. Bgl and EcoR sites were added to the 5'-and 3'-ends and subcloned into the BamH /EcoR sites of pGEX-2TK (Pharmacia) to generate pGEX2TK-CasL SH3. This plasmid was transfected into E.coli cells, and the expressed proteins were purified using the glutathione-Sepharose4B beads (Pharmacia). They were labeled with 32 P-isotope by bovine heart kinase (SIGMA) and used as the first probe.
Competent E.coli cells were infected with phages from the cDNA library (20, 000 plaque forming units/plate) and were incubated for 3 h at 43 . Then, the Hybond-C-extra membranes (Amersham) soaked in 10 mM IPTG were overlaid on phage plaques for 4 h at 37 , and these membranes were blocked in TBST buffers (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 0.05% Tween20) containing 5% skim milk.
The membranes were incubated with 0.75 µg of the isotope-labeled GST-CasL SH3
probe for 2 h at 25 , and washed, and then autoradiographed (Kodak).
Screening of a PAC Library and a Radiation Hybrid Panel Containing MICAL
Gene.
To obtain a genomic fragment containing MICAL gene, a PAC library, RPCI-1 (Roswell Park Cancer Institute) was screened by the PCR method with a pair of MICAL cDNA specific primers, P1 and P2 (described below), and we could obtain a by guest on November 17, 2017 http://www.jbc.org/
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Northern Blotting.
A polyA RNA fraction was obtained from freshly prepared murine tissues or cultured cells as described above. Two µg of this RNA fraction was loaded, electrophoresed, and hybridized with the isotope-labeled MICAL cDNA fragment.
Generation of Antibodies against Bacterially Expressed MICAL.
The cDNA fragments corresponding to the amino acid residues 884-1063 (C1) and 999-1063 (C2) of MICAL were generated by PCR, and they were inserted into pGEX1 (Pharmacia) to generate GST-MICAL C1 and GST-MICAL C2 constructs.
These plasmids were transfected into E.coli cells, and expressed fusion proteins were purified. Rabbits were immunized with these fusion proteins, and antisera against these antigens were raised (anti-MICAL C1 and anti-MICAL C2). The antisera were purified by affinity chromatography. At first, the antisera were passed through the GST-conjugated column removing anti-GST antibodies. Then, the flow-through fraction was applied onto the antigen-conjugated column, and specific antibodies bound to the column were eluted out and collected.
Plasmid Construction of Expressing Vectors and Transient Transfection.
The cDNA for HA-tag or FLAG-tag was added to the 3'-terminus of the coding sequence of MICAL, and this was inserted into pUC-CAGGS (27) or pSSRαbsr (28) by PCR using specific primers, and the M5 mutant was generated by PCR-based mutagenesis (ExSite PCR-Based Site-Directed Mutagenesis Kit: Stratagene).
Generated cDNA fragments were ligated with the HA-tag sequence, and they were inserted into the pSSRαbsr vector. The generation of c-Myc-tagged CasL was described previously (20) . To generate the FLAG-tagged vimentin expression vector, the FLAG-tag sequence was ligated to the end of the murine vimentin sequence, and this DNA fragment was inserted into the pUC-CAGGS vector.
These expression vectors were transfected into COS7 cells by the DEAE-dextran method as essentially described previously (29).
Cell Lysis, Immunoprecipitation and Immunoblotting.
Cells were lysed in 1% TritonX-100 buffer (10 mM Tris-HCl [pH 7.4], 5 mM EDTA, 150 mM NaCl, 1% TritonX-100). Cell lysates were incubated with indicated antibodies for 1 h at 4 , followed by additional incubation with the protein A-or protein G-Sepharose beads (Pharmacia). The beads were washed with 1%
TritonX-100 buffer and treated with sample buffer (2% SDS, 10% Glycerol, 60 mM
Tris-HCl [pH 6.8], 0.001% BPB). Samples were subjected to SDS-PAGE. The electrophoresed proteins were transferred to PVDF filters (MILLIPORE) and were subjected to immunoblotting, followed by detection with the AP-conjugated secondary antibody (Promega).
Immunofluorescence Microscopy.
Cells were grown on a cover glass. They were fixed with 3.7% formaldehyde, permeabilized with 0.2% TritonX-100, and they were blocked in PBS with 1% bovine serum albumin (nacala i tesque, Japan). After incubation with the primary and the secondary antibodies for 1 h at room temperature, the samples were mounted in a 1:1 mixture of 2.5% DABCO (SIGMA) in PBS and glycerol. The cells were observed under the MRC1024 confocal microscopic system (Bio-Rad).
In vitro Pull Down Assay.
For pull down assay, expressed GST fusion proteins were incubated with the glutathione-Sepharose 4B beads (Pharmacia) for 1 h at 4 C for immobilization. We prepared aliquots of cell lysates from COS7 cells transfected with MICAL and mMICAL constructs, and these aliquots were incubated with the beads for 1 h, and the proteins bound to the beads were analyzed by immunoblotting. primers in the presence of 5% DMSO. Consequently, we obtained an amplified fragment at the size of ~280 bp, and the sequence analysis of this fragment revealed that this fragment did not contain any intron sequences. These results suggest that this amplified fragment was derived from mRNA and that it was a part of the cDNA.
Since this cDNA sequence contained an in-frame stop codon at the nucleotide 48
( Fig.1A) , we concluded that we obtained the full-length coding region of this unknown gene.
The cDNA of this newly isolated gene consists of ~3700 bp nucleotides, which corresponds to the result of the Northern blotting described below. Molecular mass of the translated protein is predicted to be 118 kDa composed of 1067 amino acids.
Search of the GenBank database showed that this isolated gene encodes a novel molecule, and its amino acid sequence has prominent homology with that of KIAA0750 (35~65% homology) which had been isolated from the human brain ( 
MICAL Is Expressed in Hematopoietic Cells and Other Specific Tissues.
To assess the expression profile of the MICAL mRNA, we examined various hematopoietic cell lines and murine tissues by Northern blotting. We detected a single discrete transcript of ~3.7kb in the hematopoietic cell lines, Jurkat, HL60 and HEL ( Fig.2A) . Although we could find another larger transcript in HEL cells, the main transcript was at the size of ~3.7kb. Northern blotting of the various murine tissues revealed that MICAL mRNA expression is restricted to the several specific tissues;
we could find prominent expression in the thymus, lung, spleen, testis and faint expression in the kidney (Fig.2B ), while no obvious expression was detected in the brain, heart and liver. Even though the size of the transcript in the testis seemed to be by guest on November 17, 2017 http://www.jbc.org/ Downloaded from slightly larger than 3.7kb, this may be a spliced variant.
It has been reported that CasL is expressed prominently in the lung, kidney, placenta and lymphocytes (2, 3) . The expression pattern of MICAL corresponds to that of CasL, and this accordance supports the biological relationship between the two molecules.
Generation of Polyclonal Antibodies and Detection of MICAL Proteins.
To characterize MICAL protein, we generated polyclonal antibodies against MICAL. We used COOH-terminal regions as immunogens, C1 region spanning amino acid residues 884-1063 and C2 region 999-1063. We immunized rabbits and obtained antisera to each antigen (anti-MICAL C1 and anti-MICAL C2). The antisera were purified by affinity chromatography, and we generated specific antibodies. To check the quality of these antibodies and to detect MICAL proteins, we performed an immunoblot assay. We used lysates from COS7 cells transiently transfected with pSSRαbsr/MICAL and lysates from normally growing HeLa, 293, H9 and Jurkat cells.
Using both antibodies, we could find endogenous expression of MICAL at the size of ~120kDa in the HeLa, 293, H9 and Jurkat cells, and prominent expression in the transfected COS7 cells (Fig.3 ).
MICAL Interacts with the CasL SH3 Domain through the PPKPP Proline -Rich
Sequence.
To test the in vivo interaction between MICAL and CasL, we analyzed their interaction by transiently coexpressing MICAL and CasL proteins in COS7 cells.
When we cotransfected the FLAG-tagged MICAL (MICAL-FLAG) together with the Myc-tagged CasL (Myc-CasL), we could detect CasL in the anti-FLAG immunoprecipitates containing MICAL proteins (Fig.4A ). Alternatively, we were able to find MICAL in the anti-Myc immunoprecipitates containing CasL proteins (Fig.4A) . These results indicate that these two proteins can make a complex in mammalian cells in vivo.
To confirm that MICAL and CasL interact with each other through the CasL SH3 domain, we cotransfected MICAL-FLAG together with the Myc-tagged CasL whose SH3 domain was deleted (Myc-∆SH3 CasL), and performed immunoprecipitation. In this experiment, we could not find Myc-∆SH3 CasL in the anti-FLAG immunoprecipitates nor MICAL-FLAG in the anti-Myc immunoprecipitates (Fig.4B ).
This result indicates that MICAL and CasL interact through the CasL SH3 domain.
This interaction was also demonstrated by the in vitro pull down assay. We immobilized various GST-SH3 fusion proteins on the glutathione-Sepharose beads and incubated them with COS7 cell lysates expressing MICAL-FLAG. As shown in It has been reported that the Cas SH3 domain preferentially binds to "Pro-X-Lys-Pro: PXKP" (X: any amino acid) sequence (25). Since MICAL has a consensus sequence of "PPKPP" at the COOH-terminus, we examined if MICAL interacts with the CasL SH3 domain through this proline-rich sequence. We constructed a mutant, mMICAL-FLAG, whose proline-rich sequence PPKPP (amino acid residues 830-834) was mutated into PPAPP (Fig.4C ). When we incubated the immobilized GST-CasL SH3 and GST-Cas SH3 fusion proteins with lysates of COS7 cells expressing mMICAL-FLAG, we could not find mMICAL proteins in the complexes (Fig.4D) . These results indicate that MICAL interacts with the CasL and Cas SH3 domains through the PPKPP sequence.
MICAL Is a Cytoplasmic Protein and Colocalizes with CasL at the Perinuclear

Region.
To examine the intracellular distribution of the MICAL molecule, we performed immunofluorescence staining with the purified anti-MICAL C2 antibody. MICAL localized in the cytoplasm like filaments or meshes, and this filamentous structure spread from the perinuclear area toward the cell periphery (Fig.5a ,e). When we stained the CasL molecule, CasL also localized all over the cytoplasm, but distributed preferentially to the perinuclear area and the edge of the cell periphery (Fig.5b) . We could readily find the co-localization signals of MICAL and CasL at the perinuclear area (Fig.5c ). These results suggest that there are biological interactions between MICAL and CasL in living cells.
MICAL Also Colocalizes with Vimentin Intermediate Filaments.
MICAL is distributed in the cytoplasm like filaments in HeLa cells. Since this staining pattern was similar to that of cytoskeletal structures, we examined subcellular localization of microfilaments (F-actin), microtubules (α-tubulin) or intermediate filaments (vimentin) by co-staining these cytoskeletal molecules with MICAL.
Double staining of these proteins revealed that the staining pattern of MICAL was mostly consistent with that of vimentin ( Fig.5 middle panel) . This co-localization pattern was more apparent in 293 cells; MICAL was stained like mesh composed of fine filaments in the cytoplasm, and in many cells, strong signals were observed in the cell process areas (Fig.5 lower panel) . Therefore, MICAL was supposed to be an integrated component of vimentin intermediate filaments.
MICAL Associates with Vimentin through Its COOH-terminal Region.
To examine the possible interaction between MICAL and vimentin, we performed immunoprecipitation and immunoblotting. Prior to these experiments, we generated five deletion mutants of MICAL, M1~M5 (Fig.6A ). At first, we transfected COS7 (Fig.6B, lanes 8-10, 13) , while M1 and M2 mutants were not found in these immunocomplexes (Fig.6B, lanes 3, 4) . This result indicates that MICAL interacts with vimentin through its COOH-terminal region.
To confirm this interaction between MICAL and vimentin, we cotransfected COS7 cells with FLAG-tagged vimentin and MICAL M2 or Wt constructs, and the cell lysates were immunoprecipitated with the anti-HA antibody. As a result, we identified
Wt molecule in the anti-FLAG immunoprecipitate (Fig.6C, lane 5) , while M2 molecule was not found in the complex (Fig.6C, lane 4) .
These results clearly show that MICAL and vimentin make complexes in living cells, and that this interaction is mediated through the COOH-terminal region of MICAL. 
DISCUSSION
